EDIT vs EXC · rev $32.3M vs P/E 17, rev $23.03B
Editas Medicine Inc (EDIT) versus Exelon Corporation (EXC) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported EXC revenue for 2024-12-31 was $23.03B. Net income was $2.46B. Revenue was up 6.0% from 2023-12-31 to 2024-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
EDIT currently screens at market cap $375.2M. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Not investment advice. Open the EDIT and EXC stock pages for the full models.
Not investment advice.